BHC 031069 [83862(303989)]

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Patricia L. Morris

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO 10/582,184-Conf. #8960 Application Number **INFORMATION DISCLOSURE** Filing Date September 26, 2007 STATEMENT BY APPLICANT Lyon Bennabi First Named Inventor 1625 Art Unit

Examiner Name

Attorney Docket Number

(Use as many sheets as necessary)

of

1

Sheet

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	AA*	2001/0020030	09-06-2001	Stewart et al.				
	AB*	7,253,286	08-07-2007	Funahashi et al.				

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear		
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	ВА	WO-2002/032872-A1	04-25-2002	Eisai Co Ltd et al.			
	BB	AU-2003220935-A1	10-13-2003	Sumitomo Pharma			

Examiner	Date	
Signature	Considered	

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: November 5, 2009 Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if nossible. ⁵ Applicant is to place a check mark here if English language Translation is attached. possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/582,184-Conf. #8960	
l IN	IFORMATION	1 DI	SCLOSURE	Filing Date	September 26, 2007	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Lyon Bennabi	
(Use as many sheets as necessary)				Art Unit	1625	
				Examiner Name	Patricia L. Morris	
Sheet	2	of	2	Attorney Docket Number	BHC 031069 [83862(303989)]	

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	CA	A. Somlyo et al.: "Cell Calcium and its Regulation in Smooth Muscle," FASEB J. Vol. 3, 1989, pp. 2266-2276				
	СВ	K. E. Kamm et al.: "The Function of Myosin and Myosin Light Chain Kinase Phosphorylation in Smooth Muscle," Am. Rev. Pharmacol. Toxicol., Vol. 25, 1985, pp. 593-620				
	CC	M. Noda et al.: "Involvement of <i>rho</i> in GTPγS-induced Enhancement of Phostphorylation of 20 kDa Myosin Light Chain in Vascular Smooth Muscle Cells: Inhibition of Phosphatatse Activity," FEBS Letters, Vol 367, 1995, pp. 246-250				
	CD	M. Uehata et al.: "Calcium Sensitization of Smooth Muscle Mediated by a Rho-associated Protein Kinase in Hypertension," Nature, Vol. 389, October 30, 1997, pp. 990-994				
	CE	K. Itoh et al.: "An Essential Part for Rho-associated Kinase in the Transcellular Invasion of Tumor Cells," Nature Medicine, Vol. 5, No. 2, February 1999, pp. 221-225				
	CF	A. V. Somlyo et al.: "Rho-Kinase Inhibitor Retards Migration and <i>in Vivo</i> Dissemination of Human Prostate Cancer Cells, "Biochemical and Biophysical Research Communications, Vol. 269, 2000, pp. 652-659				
	CG	D. Gingras et al.: "Tyrosine Phosphorylatin of the Vascular Endothelial-Growth-Factor Receptor-2 (VEGFR-2) is Modulated by Rho Proteins," Biochem. J., Vol. 348, 2000, pp. 273-280				
	СН	S. Uchida et al.: "The Suppression of Small GTPase Rho Signal Transduction Pathway Inhibits Angiogenesis <i>in Vitro</i> and <i>in Vivo</i> ," Biochemical and Biophysical Research Communications, Vol. 269, 2000, pp. 633-640				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.